Early Neurological Deterioration and Time to Start Dual Antiplatelet Therapy in Patients With Acute Mild-to-Moderate Ischemic Stroke: A Pre-Specified Post Hoc Analysis of the ATAMIS Trial
Journal of Stroke · 30.09.2024 · 26 (3) · 403-414
DOI: 10.5853/jos.2024.02250 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Stroke, erschienen am 30.09.2024. Verfasst von Yu Cui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, General Hospital of Northern Theater Command, Shenyang, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Project Plan of Liaoning Province.
Themen: Schlaganfall
Abstract (Originalsprache)
Background and Purpose This study comprised a post hoc analysis of the Antiplatelet Therapy in Acute Mild to Moderate Ischemic Stroke (ATAMIS) trial aiming to determine whether the effect of dual antiplatelet therapy compared with that of monotherapy on preventing early neurological deterioration (END) differed according to the time from stroke onset to antiplatelet therapy (OTT).
Methods
In the ATAMIS trial, patients were divided into two subgroups: OTT from 0 to 24 hours (0–24 h group) and OTT from 24 to 48 hours (24–48 h group). We conducted multivariate regression analysis with continuous and categorical OTT to detect the effect of antiplatelet therapy. The primary outcome was END at 7 days, defined as an increase in the National Institutes of Health Stroke Scale (NIHSS) score of more than two points compared with the baseline. The safety outcomes were bleeding events and intracranial hemorrhage within 90 days.
Results
A total of 2,915 patients were included. With respect to END at 7 days, clopidogrel plus aspirin showed a lower proportion than aspirin alone across continuous OTT (4.8% vs. 6.7%; adjusted risk difference, -1.9%; 95% confidence interval [CI], -3.6% to -0.2%; P=0.03), and was lower in the 0–24 hours group (5.7% vs. 9.2%; adjusted risk difference, -3.7%; 95% CI, -5.5% to -2.0%; P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, General Hospital of Northern Theater Command, Shenyang, China.
Förderung
- Science and Technology Project Plan of Liaoning Province
Zitieren
APA
Cui, Y., Yao, Z. G., Zhang, J., & Chen, H. S. (2024). Early Neurological Deterioration and Time to Start Dual Antiplatelet Therapy in Patients With Acute Mild-to-Moderate Ischemic Stroke: A Pre-Specified Post Hoc Analysis of the ATAMIS Trial. Journal of Stroke, 26(3), 403-414. https://doi.org/10.5853/jos.2024.02250
Vancouver
Cui Y, Yao ZG, Zhang J, Chen HS. Early Neurological Deterioration and Time to Start Dual Antiplatelet Therapy in Patients With Acute Mild-to-Moderate Ischemic Stroke: A Pre-Specified Post Hoc Analysis of the ATAMIS Trial. Journal of Stroke. 2024;26(3):403-414. doi:10.5853/jos.2024.02250
BibTeX
@article{Cui2024,
author = {Cui, Yu and Yao, Zhi-Guo and Zhang, Jian and Chen, Hui-Sheng},
title = {Early Neurological Deterioration and Time to Start Dual Antiplatelet Therapy in Patients With Acute Mild-to-Moderate Ischemic Stroke: A Pre-Specified Post Hoc Analysis of the ATAMIS Trial},
journal = {Journal of Stroke},
year = {2024},
volume = {26},
number = {3},
pages = {403--414},
doi = {10.5853/jos.2024.02250}
}
EUVIMED